Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SHSE:688513's PEG Ratio is ranked worse than 79.57% of 93
companies
in the Biotechnology industry
Industry Median: 1.97
vs SHSE:688513: 5.51
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Chengdu Easton Biopharmaceuticals Co PEG Ratio Related Terms
Chengdu Easton Biopharmaceuticals Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co PEG Ratio Chart
SHSE:688513 vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co PEG Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a PEG Ratio of 5.51 as of Jul. 20, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 77% below median its historical median of 23.84. Over the past decade, Chengdu Easton Biopharmaceuticals Co's PEG Ratio has ranged from 0.96 to 42.52. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #74 out of 93 companies in the Biotechnology industry, placing it in the top 79.6%.
Is Chengdu Easton Biopharmaceuticals Co's PEG Ratio too high?
Chengdu Easton Biopharmaceuticals Co's current PEG Ratio of 5.51 is 77% below median its 10-year median of 23.84. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 42.52. The Biotechnology industry median PEG Ratio is 1.97. Chengdu Easton Biopharmaceuticals Co's value of 5.51 is 179.7% above this industry median. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #74 out of 93 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #74 out of 93 companies for PEG Ratio. This places Chengdu Easton Biopharmaceuticals Co in the lower half of its industry. The industry median PEG Ratio is 1.97. Chengdu Easton Biopharmaceuticals Co's value of 5.51 is 179.7% above this benchmark. Historically, Chengdu Easton Biopharmaceuticals Co's own PEG Ratio has ranged from 0.96 to 42.52 over the past decade. While the company's 10-year median is 23.84 vs. the industry median of 1.97, Chengdu Easton Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.97, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Easton Biopharmaceuticals Co's current PEG Ratio of 5.51 is 179.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Easton Biopharmaceuticals Co's current PEG Ratio is 5.51, which is 77% below median its own 10-year median of 23.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥48.16, compared to a current price of ¥57.60 — trading 19.6% above its estimated fair value. The current PEG Ratio is 5.51, which is 77% below median its 10-year median of 23.84 and 179.7% above the Biotechnology industry median of 1.97. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current PEG Ratio is 5.51 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥57.60 is trading 19.6% above its estimated GF Value™ of ¥48.16.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SHSE:688513:
PEG Ratio: 5.51 (77% below median its 10-year median of 23.84)
GF Value™: ¥48.16 vs. price of ¥57.60 (19.6% above fair value)
Industry Position: 179.7% above the Biotechnology median (#74 of 93)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
91GF Score
Get the complete analysis for SHSE:688513
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
